ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.

Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. J Clin Oncol. 2013 Apr 20,31(12):1522-9. doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Г–sterlund P, Greil R, Van Cutsem E, von Moos R, ViГ©itez JM, BouchГ© O, Borg C, Steffens CC, Alonso-OrduГ±a V, Schlichting C, Reyes-Rivera I, Bendahmane B, AndrГ© T, Kubicka S Lancet Oncol. 2013 Jan,14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

Kubicka S, Greil R, AndrГ© T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, MГјller T, Makrutzki M, Arnold D Ann Oncol. 2013 Sep,24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12.

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

Crown JP, DiГ©ras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH Jr, Tassell V, Huang X, Paolini J, Kern KA, Romieu G. J Clin Oncol. 2013 Aug 10,31(23):2870-8. doi: 10.1200/JCO.2012.43.3391. Epub 2013 Jul 15.

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

Baselga J, GГіmez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, PГЄgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, MelezГ­nkovГЎ H, Awada A. J Clin Oncol. 2013 Jul 10,31(20):2586-92. doi: 10.1200/JCO.2012.46.2408. Epub 2013 Jun 3.

[Successful cancer therapy: chance and challenges].

Greil R, Hiddemann W. Dtsch Med Wochenschr. 2013 Oct,138(41):2083. doi: 10.1055/s-0033-1349623. Epub 2013 Oct 1.

Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.

Gnant M, Greil R, Hubalek M, Steger G. Breast Care (Basel). 2013 Aug,8(4):293-9. doi: 10.1159/000354121. Review.

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

Melchardt, T, Weiss, L, Greil, R, Egle, A, Magazine of European Medical Oncology. 2013, Volume 6, Issue 3: 193-196.

Antiapoptotic effects of p21 regarding its subcellular localization in arsenic trioxide induced apoptosis in CLL

Sifft, E, Hofbauer, JP, Asslaber, D, Hartmann, TN, Merkel, O, Greil, R ONKOLOGIE. 2013, 36: 222-222.

The transcription factor IRF-4 is related to prognosis in Chronic Lymphocytic Leukemia (CLL) and involved in proliferation and survival

Asslaber, D, Hofbauer, JP, Zaborsky, N, Kocher, T, Hartmann, TN, Greil, R, Egle, A ONKOLOGIE. 2013, 36: 222-223.